Skip to main content
$1.89 -$0.07 (-3.6%)

04:00 PM EDT on 10/26/21

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CAPS Rating: 2 out of 5

A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.

Current Price $1.89 Mkt Cap $312.8M
Open $1.95 P/E Ratio 0.00
Prev. Close $1.89 Div. (Yield) $0.00 (0.0%)
Daily Range $1.88 - $1.96 Volume 1,595,334
52-Wk Range $1.88 - $5.24 Avg. Daily Vol. 2,242,379

Caps

How do you think NASDAQ:SPPI will perform against the market?

Add Stock to CAPS Watchlist

All Players

407 Outperform
13 Underperform
 

All-Star Players

31 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SPPI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

GunnarVagotis (76.69)
Submitted April 02, 2013

I have held NBIX for about 5 years and am just now in the black after having been deeply in the red the entire time. What's the message? GO LONG IN A BUNCH MORE SPECULATIVE BIOTECH STOCKS.

pavlos1971 (29.42)
Submitted March 13, 2013

From @adamfeuerstein's tweet: "$SPPI -- What happened? 1) Wholesalers didn't order any Fusilev in Q1 2) Hospital demand for Fusilev fell off cliff due to generics."

NASDAQ:SPPI VS S&P 500 (SPY)

Fools bullish on NASDAQ:SPPI are also bullish on:

Fools bearish on NASDAQ:SPPI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SPPI.

Recs

0
Member Avatar mdriver78 (75.42) Submitted: 11/19/2020 9:46:38 AM : Outperform Start Price: $4.25 NASDAQ:SPPI Score: -83.77

Spectrum, the therapy has less to do with treating cancer than treating the side effects of cancer drugs.

As you know, many common chemotherapies have severe side effects. In suppressing the existence and growth of cancer cells, some types of chemotherapies also suppress normal cells in our body. This is particularly true of cell lines that are naturally rapidly dividing and growing.

It’s one reason why some chemo patients lose their hair.

Hair loss can be distressing and unsightly, but some other side effects are hidden, and far worse. One of these is neutropenia, caused by the ongoing destruction of neutrophils, an abundant type of white blood cell important for our immune system to function.

The decrease in these white blood cells makes a patient far more vulnerable to infection, since these little soldier cells aren’t around in enough numbers to do perform their defensive duties. Moreover, and ironically, these cells are needed to fight off cancer! Reducing their numbers makes it more likely that a cancer will come back stronger than ever once it has adapted to a chemotherapy drug.

Spectrum’s experimental therapy eflapegrastim is designed to combat neutropenia by increasing the production of neutrophils. The drug contains an analogue of a messaging molecule called granulocyte-colony stimulating factor (G-CSF). G-CSF, when present, stimulates the production of neutrophil precursors. This process is tightly regulated under normal circumstances, so that the number of circulating neutrophils is appropriate for immune system defense.

But this G-CSF analogue is also bound to a targeting molecule derived from antibodies. This targeting molecule helps prolong the half-life of the therapy in the body while also binding to bone marrow cells responsible for neutrophil production. There, they help stimulate production of fresh neutrophils.

Spectrum has successfully completed Phase 3 trials for eflapegrastim showing its ability to support healthier levels of neutrophils, and even submitted for FDA approval.

However, the original date for the FDA to make a decision has passed. The regulator wasn’t able to make its Oct. 24 due date thanks to COVID-19 preventing travel to inspect manufacturing facilities in South Korea, where this therapeutic is manufactured.

While no exact date is available, eventually the FDA will be able to perform site inspection in South Korea. Once this happens, the regulator will then be able to decide on this therapy. Could potentially be just weeks away from this important catalyst, which if navigated successfully could provide a huge boost to SPPI shares.

Moreover, the company is expecting data for a different therapy next month. The drug in question is designed to suppress cancer by binding to endothelial growth factor receptors (EGFRs) in patients with nonsmall-cell lung cancers (NSCLC) with a specific mutation in EGFR or HER2 genes.

Spectrum expects it will have top-line data from the third cohort of a Phase 2 trial by the end of the year. The company plans to update once data are available, and a successful outcome could be used to launch into a Phase 3 trial or even possibly furnish the necessary support for a New Drug Application. Strong data could provide an even bigger boost to SPPI’s valuation than the FDA approval for eflapegrastim.

Recs

0
Member Avatar BlizzardInv (< 20) Submitted: 12/13/2013 3:59:22 PM : Outperform Start Price: $9.12 NASDAQ:SPPI Score: -235.30

Totally a speculative bet.

the company is definitely improving though and their pipeline is pretty promising. new drugs possibly coming out in the next few years and their way of aquisitioning other companies is pretty awesome.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 9/26/2013 5:46:03 AM : Underperform Start Price: $8.14 NASDAQ:SPPI Score: +246.10

top hs pattern

Leaderboard

Find the members with the highest scoring picks in SPPI.

Score Leader

missash

missash (< 20) Score: +382.10

The Score Leader is the player with the highest score across all their picks in SPPI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
missash < 20 11/9/2009 Underperform 3Y $4.69 -59.67% +322.43% +382.10 0 Comment
RedlyneTheory 50.25 3/28/2011 Underperform 3Y $8.41 -77.52% +246.33% +323.85 0 Comment
PiotroskiPicks 78.41 4/6/2011 Underperform 1Y $9.14 -79.31% +241.82% +321.14 0 Comment
Dare33 < 20 5/27/2011 Underperform 1Y $9.03 -79.07% +241.58% +320.65 0 Comment
alleyspins < 20 10/1/2012 Underperform 5Y $11.58 -83.68% +215.53% +299.22 0 Comment
streetcat1 33.87 11/9/2007 Underperform 3W $3.34 -43.33% +228.07% +271.40 0 Comment
JeffnTeri < 20 6/24/2013 Underperform 5Y $7.60 -75.13% +189.70% +264.83 0 Comment
SqwiiTrader < 20 9/26/2013 Underperform 5Y $8.14 -76.78% +169.32% +246.10 1 Comment
robslap1 58.26 8/5/2013 Underperform 5Y $8.36 -77.39% +167.20% +244.60 0 Comment
biotechf 68.62 2/8/2016 Underperform 5Y $4.58 -58.73% +145.47% +204.20 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SPPI.